Vytrus Bitotech does not slow down its growth in the first section of 2025. The company specializing in active ingredients derived from plant biotechnology for the cosmetic industry, has presented its unaudited results advance corresponding to the first quarter of 2025 and registers a growth of 76% in its sales compared to the same period of the previous year.
The company established in Catalonia has experienced an increase in sales in all the geographical areas in which it operates. In Spain, for example, this increase has reached 64%, in the United States, they have exceeded 25% and, especially, this increase is notable in Asia-Pacific, with 271% and India becoming the main driver. Latin America has grown by 56% thanks to key markets such as Colombia, Mexico and Brazil.
Vytrus manages to exceed 5.9 million euros in interannual sales for the first time and improves its profitability with an EBITDA that doubles by +102% compared to the same period of the previous year and reaches 1.02 million euros.
The strategic plan continues to reflect its avid objective of tripling its sales to reach 12 million euros and thus also quadruple its EBITDA to 5 million by 2027, as indicated in the roadmap presented in 2024.
This last month, Vytrus Biotech has also celebrated the recognition obtained in one of the most prestigious fairs in the cosmetic sector such as in-cosmetics Global. In Amsterdam, the company was awarded the Silver Best Ingredient Award within the framework of the Innovations Awards. In addition, it presented its latest launch to the attendees of the fair: Clarivine. With this, it completes a portfolio of 22 active ingredients.